Palavras-chave
Neoplasias encefálicas
Terapêutica
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Descobrir qual o resultado do uso de vírus oncolíticos (VO) para a terapêutica de câncer cerebral, observando seus diferentes mecanismos de ação e vantagens ou desvantagens específicas. Métodos: Esta revisão integrativa selecionou 30 artigos nas seguintes bases de dados: MedLine, Pubmed e IBECS. Incluíram-se estudos clínicos, pré-clínicos e experimentações in vitro publicados de 2020 a 2025. Resultados: Vários vírus oncolíticos se mostraram eficazes no combate ao câncer cerebral, evidenciando a capacidade para induzir a desintegração de células cancerosas. Os estudos ressaltaram mecanismos como lise celular, ajuste imunológico, obstrução de PD-1 e potencial sinergia com outras modalidades terapêuticas. Desafios como a distribuição efetiva do vírus, a resposta imune do sujeito e a toxicidade necessitam ser superados para uma implementação clínica. Visto que, a acurácia dos VO na identificação de células tumorais e sua capacidade de alteração do tumor são vantagens notáveis, indicando um potencial se combinados com as terapias tradicionais. Considerações finais: A terapia viral oncolítica surge como uma nova possibilidade terapêutica, sendo necessários mais estudos para verificar sua eficiência e segurança em grupos maiores de pacientes.
Referências
BOMMAREDDY PK, et al. Oncolytic herpes Simplex virus expressing IL-2 controls glioblastoma growth and improves survival. Journal for Immunotherapy of Cancer, 2024; 12(4).
CALDERÓN-PELÁEZ MA, et al. Zika Virus: A Neurotropic Warrior against High-Grade Gliomas—Unveiling Its Potential for Oncolytic Virotherapy. Viruses, 2024; 16(4): 561.
CHEN Y, et al. HSV-1-induced N6-methyladenosine reprogramming via ICP0-mediated suppression of METTL14 potentiates oncolytic activity in glioma. Cell Reports, 2024; 42(10).
DE LA NAVA D, et al. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro-oncology, 2024; 26(8): 1509-1525.
FARES J, et al. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. The Lancet Oncology, 2021; 22(8): 1103-1114.
FERREIRA RS, et al. Differential Replication and Oncolytic Effects of Zika Virus in Aggressive CNS Tumor Cells: Insights from Organoid and Tumoroid Models. Viruses, 2024; 16(11): 1764.
GÁLLEGO PÉREZ-LARRAYA J, et al. Vírus oncolítico DNX-2401 para glioma pontino intrínseco difuso pediátrico. New England Journal of Medicine, 2022; 386(26): 2471-2481.
GARCÍA-ROMERO N, et al. Newcastle disease virus (NDV) oncolytic activity in human glioma tumors is dependent on CDKN2A-type I IFN gene cluster codeletion. Cells, 2020; 9(6): 1405.
GHAJAR-RAHIMI G, et al. Clinical advances in oncolytic virotherapy for pediatric brain tumors. Pharmacology & therapeutics, 2022; 239: 108193.
HADDAD AF, et al. Immunologic aspects of viral therapy for glioblastoma and implications for interactions with immunotherapies. Journal of neuro-oncology, 2021; 152: 1-13.
HONG B, et al. PKR induces TGF-β and limits oncolytic immune therapy. Journal for immunotherapy of cancer, 2023; 11(2).
LAL S, RAFFEL C. Protocols to Manufacture an Oncolytic Measles Virus–Sensitive Immunocompetent Mouse Model of Medulloblastoma. Medulloblastoma: Methods and Protocols, 2022; 2423: 165-177.
LIU Y, et al. Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis. CNS Neuroscience & Therapeutics, 2024; 30(11).
MELÉNDEZ-VÁZQUEZ NM, et al. Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas. Viruses, 2024; 16(11): 1775.
MONIE DD, et al. Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas. Scientific reports, 2021; 11(1): 11198.
NASSIRI F, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nature medicine, 2023; 29(6): 1370-1378.
NIEBLAS‐BEDOLLA E, et al. Emerging immunotherapies in the treatment of brain metastases. The Oncologist, 2021; 26(3): 231-241.
NING W, et al. Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial. Nature Communications, 2024; 15(1): 9299.
NOH MH, et al. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro-oncology, 2024; 26(9): 1602-1616.
PANAGIOTI E, et al. Immunostimulatory bacterial antigen–armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. The Journal of clinical investigation, 2021; 131(13).
RIVADENEIRA DB, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity, 2019; 51(3): 548-560.
RONG L, et al. Emerging therapies for glioblastoma: Current state and future directions. Journal of Experimental & Clinical Cancer Research, 2022; 41(1): 1-18.
SAHA D, RABKIN SD. Immunohistochemistry for tumor-infiltrating immune cells after oncolytic virotherapy. Oncolytic Viruses, 2020; 2058: 179-190.
SURYAWANSHI YR, SCHULZE AJ. Oncolytic viruses for malignant glioma: On the verge of success?. Viruses, 2021; 13(7): 1294.
TODO T, et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma. Nature communications, 2022; 13(1): 4119.
TODO T, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nature medicine, 2022; 28(8): 1630-1639.
VAN PUTTEN EHP, et al. Convection enhanced delivery of the oncolytic adenovirus delta24-RGD in patients with recurrent GBM: a phase I clinical trial including correlative studies. Clinical Cancer Research, 2022; 28(8): 1572-1585
ZENG J, et al. Oncolytic viro-immunotherapy: an emerging option in the treatment of gliomas. Frontiers in immunology, 2021; 12: 721830.
ZHANG J, et al. Oncolytic HSV-1 suppresses cell invasion through downregulating Sp1 in experimental glioblastoma. Cellular Signalling, 2023; 103: 110581.
ZHU G, et al. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma. Cancer Immunology, Immunotherapy, 2022; 71(10): 2433-2448.